Skip to content

Henry Schein

US · HSIC #1526 by market cap Listed 1970
83.52 -1.28 -1.51%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Fair Value how this is computed

Near fair value
60.08 fair value ≈ 71.85 83.62
  • Implied fair-value range of 60.08-83.62, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +16.2% above the average-multiple fair value of 71.85.

Valuation each multiple against its own 5-year range

P/B ratio 3.02 Expensive vs history 79th percentile
5-year average 2.78 · #4 of 8 in Medical Distribution
P/E ratio 23.62 Expensive vs history 71st percentile
5-year average 21.97 · forward 17.54 · #3 of 6 in Medical Distribution
P/S ratio 0.69 Cheap vs history 24th percentile
5-year average 0.76 · forward 0.67 · #9 of 12 in Medical Distribution

Vs. peers Medical Distribution

Company Market cap P/E (TTM) P/B Div yield
Henry Schein (HSIC) 9.23B 22.88 2.92 0.00%
McKesson (MCK) 123.47B 27.48 -31.23 0.32%
Cencora (COR) 64.71B 18.89 17.58 0.71%
Cardinal Health (CAH) 63.06B 35.29 -20.84 0.75%
Akso Health (AHG) 1.08B -42.00 5.97 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value76.32 Economic moatNarrow UncertaintyHigh

Trading 8.6% above Morningstar's fair value estimate.

Fair value

Henry Schein Inc is assigned a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 13% premium over our quantitative fair value estimate of $76.32 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's unfavorable dividend structure undermines our estimated valuation. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which sits in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are expensive.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 33.2%, a core component of valuation, falls in the bottom 30% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:01:08 · For reference only, not investment advice and not tailored to your situation.

Henry Schein discussion 0 comments

Add a comment